A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn’s Disease

A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn’s Disease

BackgroundInfliximab is effective in inducing and maintaining remission in patients with Crohn’s disease (CD), but primary non-response (PNR) occurs in 10-30% of cases. We investigated whether serum biomarkers are effective in predicting PNR in patients with CD.MethodsFrom January 2016 to April 2020...

Full description

Bibliographic Details
Main Authors: Li Li, Rirong Chen, Yingfan Zhang, Gaoshi Zhou, Baili Chen, Zhirong Zeng, Minhu Chen, Shenghong Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Immunology
Subjects:
Crohn’s disease
primary non-response
infliximab
serum biomarkers
prediction
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.646673/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.646673/full

Similar Items